Fosamax Caused Femur Fracture in Both Thighs, According to Maryland Woman’s Lawsuit

Share Article

Parker Waichman LLP has filed a lawsuit alleging that Merck’s Fosamax (alendronate) caused two femur fractures in a Maryland woman. According to the suit, Fosamax and other bisphosphonates can increase the risk of atypical femur fractures.

News Image

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a Fosamax lawsuit naming Merck Sharp & Dohme Corp., Merck & Co., Inc. and other potential manufacturers (John Doe Drug Companies 1-100) as Defendants. The suit was filed on July 5th in the Superior Court of New Jersey, Atlantic County Law Division (Docket No. L-4569-12).

According to the Complaint, the Plaintiff started taking Fosamax around May 2002. During the course of her treatment with the drug, the Plaintiff suffered from two femur fractures. The most recent of these injuries occurred in July 2009 when she experienced a break in her left thighbone. The suit alleges that her injuries are a direct result of using Fosamax for a number of years, and claims severe mental and physical pain and suffering, permanent injuries, emotional distress, economic loss due to medical expenses and living related expenses due to a new lifestyle.

The lawsuit holds the Defendants responsible for failing to warn users about the risk of Fosamax. According to the lawsuit, there has been sufficient evidence suggesting that the drug can make bones more brittle and vulnerable to fractures.

Fosamax is approved to treat conditions such as osteoporosis in postmenopausal women. It is part of the bisphosphonate drug class, a category that also includes medications such as Actonel and Boniva. In October 2010, the U.S. Food and Drug Administration (FDA) updated the label on bisphosphonate drugs to warn about the risk of atypical fractures of the thigh, also referred to subtrochanteric and diaphyseal femur fractures.

In addition to the fracture risk, the FDA has also recently questioned the value of using Fosamax and other bisphosphonates as a long-term therapy in women. In May, the agency published a review in the New England Journal of Medicine after studying data from over 2,300 postmenopausal women; overall, the research suggested that there is little reason to use the drugs for longer than five years.

Another study, published in the Archives of Internal Medicine, compared patients with classic femur fractures versus those with atypical femur fractures. Among the atypical fracture group, 82 percent were identified as having taken bisphosphonates.

Parker Waichman LLP continues to offer free legal consultations to victims of Fosamax side effects. If you or a loved experienced an atypical femur fracture and you believe Fosamax is to blame, please contact their office by visiting the firm’s Fosamax website. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz, Managing Attorney
Follow us on
Visit website